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Take Home Message 43 
We analysed recovery after radical cystectomy using multiple domains reflecting 44 
mobilisation (steps per day), exercise capacity (chair to stand), disability, HRQOL and health 45 
economics. We found most patients recovered most of their physical capacity by 12 weeks 46 
of surgery. 47 
 48 
Tweet 49 
Activity trackers help measure recovery after major surgery 50 
 51 
 52 
Letter 53 
Many patients develop complications after Radical cystectomy (RC) [1]. Reductions in 54 
morbidity have occurred through centralization, technical improvements [2] and perhaps 55 
through Robot-assisted RC (RARC). Whilst RARC is gaining popularity, there are concerns 56 
about oncological safety [3], extra-corporeal reconstruction [4] and RCTs find little 57 
difference [5]. We are conducting a prospective RCT comparing open RC and RARC with 58 
mandated intra-corporeal reconstruction (iROC [6]). Within this trial we quantify recovery 59 
using multiple domains: personal activity trackers, the 30 second Chair Stand Test (CST30), 60 
and qualitative questionnaires of disability (WHODAS 2.0), HRQOL (EORTC QLQ-C30 and 61 
QLQ-BLM30 [6]) and health economics (EQ-5D-5L).  62 
 63 
Given that little is known of these tools in this setting, we included an internal analysis when 64 
the first 30 patients reached the primary outcome (90 days after RC). This was reached 209 65 
days after the first recruitment and included 28/30 who underwent their allocated RC 66 
(supplementary figures, supplementary table 1). The average time to discharge was 11.0 67 
days (st dev. ± 5.7), and following discharge 20/28 (71%) patients visited their GP or A&E, 68 
and 5/28 (18%) were readmitted to hospital. Within 90 days of surgery, the average 69 
duration out of healthcare was 76.6 ± 6.7 days. Post-operative complications were seen in 70 
15/28 patients, including; Clavien-Dindo Grade 1 in 5/28, Grade 2 in 7/28 and grade 3a/3b in 71 
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3/28 (11%, supplementary tables). Baseline compliance varied from 22/28 (79%) for activity 72 
trackers, 24/28 (86%) for CST30, 27/28 (96%) for WHODAS 2.0, 27/28 (96%) for QLQ-C30, to 73 
28/28 (100%) for EQ-5D-5L. The observed values (figure 1) matched the general population 74 
(e.g. average WHODAS 2.0 score (15%) was within 78% of general population, CTS30 75 
(average 13) was similar to that for >65 year old males and >60 year old females [7]) or were 76 
slightly lower (age matched Canadian men and women walked 7,869 and 6,970/steps per 77 
day, respectively [8]). Compliance with activity trackers and CTS30 improved during 78 
recruitment as the trial staff became experienced with collection during the perioperative 79 
period. 80 
 81 
Each measure deteriorated after surgery (figure 2). At day 5 (POD5) the average number of 82 
daily steps was 1840 ± 1348 (32±22% baseline) and CTS30 was 8.3±5.3 (62.0±38% baseline). 83 
Activities levels improved such that by week 5 walking reached 74±32% of the baseline 84 
(4294±2370 steps/day) and CTS30 reached 96±35% baseline (12±4.3/30 seconds). By week 85 
12 many patients had returned to their baseline level of activity (average steps/day 86 
6375±3246, 99±47% baseline and CTS30 13±5, 108±33%). Patient reported qualitative 87 
disability scores contrasted activity levels. At week 5, WHODAS 2.0 disability reached 88 
26±22% (which was 2.9±3.3 fold higher than at baseline), before returning to pre-operative 89 
levels in most patients by week 12 (0.9±1.1 fold baseline). Changes in EQ-5D-5L scores rating 90 
‘health today’(Q6) and QLQ-C30 (Q29: overall health and Q30: QOL in past week) 91 
questionnaires mirrored activity levels with lower scores in week 5 (EQ-5D-5L 84±17%, QLQ-92 
C30(Q29) 80±22% and QLQ-C30(Q30) 78±23% of baseline) that recovered to baseline by 93 
week 12 (93±17%, 98±16% and 93±16%, respectively). Patients seeking medical review after 94 
discharge (GP, A&E or hospital admission) averaged fewer daily steps at week 5 (medical 95 
review: 4069±2526 vs. no review: 4743±2132) and week 12 (5535±1786 vs. 6724±3703), and 96 
had lower absolute CTS30 numbers at the same times (week 5: 11.2±4.3 vs. 13.0±4.4 and 97 
week 12: 13.2±5.5 vs. 13.5±3.1), although the low sample size precluded meaningful 98 
statistical comparison. We hypothesised that multiple domains are needed to robustly 99 
measure recovery after RC and that accurate measurement will allow a meaningful 100 
comparison between open RC and RARC. Correlation of baseline data revealed no significant 101 
associations between measures of activity, qualitative disability or QOL data (Pearson 102 
correlation all p>0.08). Average daily steps was not correlated to CTS30 (r=-0.08, p=0.7 in 20 103 
 4 
patients) and was closest to the QLQ-C30 domain reflecting QOL (r=0.41, p=0.08). In this 104 
small sample size, one could hypothesise that daily steps reflect actual activity whilst CTS30 105 
is a measure of lower limb strength and exercise capacity (which may not be used).  106 
 107 
In conclusion, we report multi-domain measurements of recovery after RC. Our measures 108 
appear well tolerated by patients, are applicable to routine practice, are likely to be useful 109 
within our RCT and in the RC pathway.   110 
 5 
Figure legends 111 
Figure 1. Distribution of multi-domain measurements at recruitment (baseline). 112 
Figure 2. Multi-domain measurements of RC recovery over the first 26 weeks after RC. 113 
Supplementary figure 1. Recruitment within iROC. a). Consort diagram of iROC feasibility 114 
phase recruitment and b). histogram of length of stay and primary outcome measure (days 115 
alive out of hospital/healthcare). 116 
Supplementary figure 2. Recruitment within iROC. 117 
Supplementary Table 1. Patients and tumours within the iROC feasibility phase.  118 
Supplementary table 2. Complications seen after surgery. 119 
 120 
 121 
  122 
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Supplementary table 1. Patient features within the iROC feasibility phase. 148 
 149 
 150 
    n % 
Sex   
 Male 23 76.7% 
 Female 7 23.3% 
Age   
 Average ± st. dev. 67.9 ± 11.7 
 >75 10 33.3% 
ASA   
 1 5 16.7% 
 2 12 40.0% 
 3 4 13.3% 
 Missing 9 30.0% 
Reconstruction   
 Ileal conduit 22 73.3% 
 Neobladder 5 16.7% 
 Missing 1 3.3% 
BMI   
  Average ± st. dev. 27.01 ± 3.4 
 151 
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Supplementary table 2. Complications seen after surgery. 155 
 156 
Patient 
Grade of 
complication Detail 
2 Grade II Systemic sepsis, ileus, blocked catheter 
3 Grade II Infection of unknown origin  
6 Grade I Wound - Hernia  
7 Grade I Gastrointestinal - ileus and emesis 
8 Grade IIIb Surgical - Incisional hernia. Small bowel obstruction 
10 Grade II Wound - Wound infection  
11 Grade II Genitourinary - Urosepsis and renal failure  
13 Grade I Gastrointestinal - Diarrhoea  
19 Grade II Cardiac - Arrhythmia  
20 Grade I Scrotal swelling. Anaemia not requiring transfusion 
21 Grade IIIb Obstructed common Bile Duct. Urinary infection. 
26 Grade I Gastrointestinal - Constipation  
27 Grade IIIb Cardiac - Myocardial infarction  
31 Grade II Ileus. TPN line. 
34 Grade II Oral Thrush 
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